@agrothey @DocCatenacci @MPishvaian Strongly agree and drives us crazy when metastatic protocols require it. We almost end up dropping for cycle #2. Time to get this incorporated into protocols.
English
blase polite
4 posts
blase polite
@BlasePolite
GI medical oncologist, cancer health policy expert, deadhead, husband and father of 2
Katılım Ocak 2020
19 Takip Edilen122 Takipçiler
@DocCatenacci @MPishvaian I strongly believe that no patient with an advanced cancer should get bolus 5-FU
English
#TumorBoardTuesday
1/3 CASE: 35 y/o F w stage 4 (diffuse supraclav/RP M1 LNs) GEJ AC, HER2 IHC3+, PD on 1L FOLFOX-trastuzumab after ~12m w new lung&peritoneal dz. Repeat EGD w bx: HER2 IHC3+/CPS 0. ctDNA profile NO HER2 amp (TP53 mt MAF 9.3%).
How would u treat this pt now?
#TumorBoardTuesday@TumorBoardTues
#MedTwitter #OncTwitter 🏈We hope your Sunday was SUPER, whether U were rooting for Mahomes or Brady🏈 Now, it's time to 💭about our next #TumorBoardTuesday ➡️Tuesday 02/09/21 8-9 PM EST @DocCatenacci presents a case of a pt with HER2+ GEA considering 2L Tx #GEA #GEAwesome
English
blase polite retweetledi
blase polite retweetledi
Updated survival data from the BEACON study. Doublet encorafenib and cetuximab as good as triplet therapy in BRAF mutant mCRC. #GI20
English
blase polite retweetledi
DART results finally published, congrats! Problem is, I still don't know what patients were enrolled (well diff vs. poorly diff??). Not all G3 NENs are poorly diff NECs and G3 NETs and G3 NECs are different beasts. But there is a signal... :) clincancerres.aacrjournals.org/content/early/…
English